Firmonertinib Combine With Carboplatin/Cisplatin and Pemetrexed as Neoadjuvant Therapy for Resectable Stage II-IIIB EGFR Sensitive Mutanted NSCLC
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Firmonertinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Mar 2025 New trial record